American Journal of Cardiovascular Drugs

, Volume 3, Issue 3, pp 193–200

Preventing Renal Dysfunction in Patients with Hypertension

Clinical Implications from the Early AASK Trial Results

Authors

    • Emory University School of Medicine
  • Denyse T. Brown
    • University of Alabama at Birmingham
  • Michael Lipkowitz
    • Mount Sinai School of Medicine
  • John Middleton
    • University of Texas-Southwestern
  • Keith Norris
    • Martin Luther KingJr/Charles Drew University
  • AASK Study Group
Review Article

DOI: 10.2165/00129784-200303030-00005

Cite this article as:
Lea, J.P., Brown, D.T., Lipkowitz, M. et al. Am J Cardiovasc Drugs (2003) 3: 193. doi:10.2165/00129784-200303030-00005

Abstract

Strategies to delay progression of established renal disease have primarily been directed at examining the class of antihypertensive therapy and/or the level of blood pressure control. In diabetic renal disease many trials have noted a protective role of ACE inhibitor-based therapy over non-ACE inhibitor-based therapy. This paper reviews recent clinical trials evaluating hypertension-related kidney disease including the interim results of the African-American Study of Kidney Diseases and Hypertension (AASK) Study, to date the largest prospective study of African-American patients with kidney disease due to hypertension. This trial reports a renoprotective effect of ACE inhibitor-based therapy over calcium-channel antagonist- based therapy. The renoprotective effect of ACE inhibitor-based therapy may, in part, be due to their antiproteinuric effect independent of blood pressure lowering.

Copyright information

© Adis Data Information BV 2003